By Fineline Cube 
SicaGene (Beijing) Biotechnology Co., LTD announced that SG12 injection, a self-developed antisense oligonucleotide (ASO), has received NMPA clinical trial approval for the treatment of chronic hepatitis B (CHB). The drug, designed to be complementary to key HBV mRNA sequences, effectively inhibits viral protein synthesis—specifically hepatitis B surface antigen (HBsAg)—with the goal of achieving functional clinical cure through HBsAg reduction or clearance. The milestone validates SicaGene’s next-generation oligonucleotide platform and positions the veteran team (with BeOne and Ionis pedigree) to address the 250+ million global CHB population.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA) |
| Approval Type | Clinical trial authorization (IND) |
| Product | SG12 injection |
| Drug Class | Antisense oligonucleotide (ASO) – next-generation single-stranded |
| Mechanism | Complementary binding to HBV mRNA → inhibits viral protein synthesis |
| Primary Target | Hepatitis B surface antigen (HBsAg) |
| Indication | Chronic hepatitis B (CHB) |
| Developer | SicaGene (Beijing) Biotechnology Co., LTD |
| Team Pedigree | Veterans from BeOne, Ionis (oligonucleotide R&D, clinical, industrialization) |
| Approval Date | 9 Mar 2026 |
Drug Profile & Mechanism
| Attribute | SG12 Specification |
|---|---|
| Architecture | Single-stranded antisense oligonucleotide |
| Target Sequence | Key HBV mRNA sequences (complementary design) |
| Mechanism of Action | • Binds to HBV mRNA • Blocks translation of viral proteins • Specifically reduces HBsAg synthesis |
| Therapeutic Goal | Functional cure: HBsAg reduction/clearance → restoration of innate immune response |
| Delivery | Injection formulation (likely subcutaneous or intravenous) |
| Platform | Next-generation oligonucleotide chemistry (enhanced stability, potency, tissue distribution) |
Functional Cure Rationale:
- HBsAg as Barrier: Persistent HBsAg induces immune tolerance; clearance required to reactivate host anti-HBV immunity
- ASO Advantage: Direct mRNA targeting vs. nucleos(t)ide analogs (viral suppression only); potential for finite treatment duration
- Combination Strategy: SG12 + pegylated interferon or therapeutic vaccine may enhance cure rates
Market Context & Competitive Landscape
| Factor | Market Implication |
|---|---|
| Global CHB Burden | 296 million chronic infections; 820,000 annual deaths from cirrhosis/HCC |
| Current Standard | Nucleos(t)ide analogs (entecavir, tenofovir) – viral suppression, not cure; lifelong therapy |
| Functional Cure Gap | <1% spontaneous HBsAg clearance; huge unmet need for finite therapies |
| ASO Competition | Vir Biotechnology (VIR-2218), Ionis (bepirovirsen), Arrowhead (ARO-HBV) in Phase II/III |
| China Market | 90 million CHB patients; government priority for curative therapies; domestic innovation incentivized |
Competitive Dynamics
| Competitor | Product | Mechanism | Status | SG12 Differentiation |
|---|---|---|---|---|
| GSK/Vir | Bepirovirsen (Ionis) | ASO targeting all HBV RNAs | Phase III | First-to-market potential; SG12 next-gen chemistry may improve efficacy/tolerability |
| Arrowhead | ARO-HBV (JNJ-3989) | siRNA targeting HBV transcripts | Phase II | RNAi vs. ASO mechanism; combination approaches converging |
| Assembly Bio | Vebicorvir | Core inhibitor + ASO combos | Phase II | Small molecule + oligonucleotide combinations |
| SicaGene | SG12 | Next-gen ASO targeting HBsAg | Phase I-ready | China-developed; veteran Ionis/BeOne team; potential cost/manufacturing advantage |
Development Outlook
| Phase | Timeline | Objectives |
|---|---|---|
| Phase I | 2026-2027 | Safety, tolerability, PK/PD; HBsAg reduction kinetics; dose-ranging |
| Phase II | 2027-2029 | Efficacy in CHB patients; combination with NA backbone; functional cure rates |
| Phase III | 2029-2031 | Head-to-head or non-inferiority vs. bepirovirsen; China NDA; global partnership |
| Global Strategy | 2028+ | U.S./EU IND filing; Fast Track designation; licensing discussions with multinational pharma |
Strategic Value
- Team Differentiation: Ionis/BeOne veterans bring 20+ years oligonucleotide drug development experience; de-risked platform execution
- China Advantage: Domestic regulatory pathway; potential for NRDL inclusion; government support for hepatitis elimination goals
- Platform Expandability: ASO technology applicable to other viral diseases (HDV, HPV) and genetic disorders
- Partnership Potential: Attractive asset for global pharma seeking China market entry + oligonucleotide manufacturing capabilities
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, functional cure achievement, and competitive positioning for SG12. Actual results may differ due to ASO delivery challenges, viral escape mechanisms, and competitive dynamics in the hepatitis B curative therapy race.-Fineline Info & Tech